← back to search

Jana Prausová

Proton Therapy Centre ·
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments, Cancer Treatment and Pharmacology, and Gastric Cancer Management and Outcomes.
h-index
25
citations
7,250
works
93
NIH funding
primary concept
Medicine
email

Recent publications

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Journal of Clinical Oncology 2024cited by 148position: middledoi
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology 2019cited by 280position: middledoi
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
Annals of Oncology 2018cited by 65position: middledoi
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Annals of Oncology 2017cited by 104position: middledoi
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
Annals of Oncology 2016cited by 71position: middledoi
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
European Journal of Cancer 2013cited by 238position: middledoi
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Annals of Oncology 2013cited by 103position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eric Van Cutsem · KU Leuven4 papers (2013–2018)Josep Tabernero · Medical Research Network4 papers (2013–2018)Radka Obermannová · Masaryk University3 papers (2016–2018)David C. Portnoy · University of Tennessee at Knoxville3 papers (2016–2018)G. Bodoky · Unified Szent István and Szent László Hospital3 papers (2016–2018)Rocio García‐Carbonero · Research Institute Hospital 12 de Octubre3 papers (2016–2018)Federico Nasroulah · Bristol-Myers Squibb (United States)3 papers (2016–2018)Takayuki Yoshino · Kindai University3 papers (2016–2018)Allen Lee Cohn · Canon (United States)3 papers (2016–2018)Tudor–Eliade Ciuleanu · Iuliu Hațieganu University of Medicine and Pharmacy3 papers (2016–2018)Rebecca R. Hozak · Eli Lilly (United States)2 papers (2017–2018)Kentaro Yamazaki · The University of Tokyo2 papers (2016–2018)Sara Lonardi · Istituto Oncologico Veneto2 papers (2016–2018)Kei Muro · The University of Tokyo2 papers (2017–2018) · 1 papers (2013–2013) · 1 papers (2018–2018)Julien Taı̈eb · Assistance Publique – Hôpitaux de Paris1 papers (2018–2018) · 1 papers (2013–2013)P. Clingan · Cancer Council NSW1 papers (2016–2016) · 1 papers (2017–2017)